Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 322

1.

Launching APOLLO: The Role of APOL1 Genetic Variants in Live- and Deceased-Donor Kidney Transplantation.

Fuentes F, Kopp JB.

Kidney Int Rep. 2019 Dec 27;5(3):252-254. doi: 10.1016/j.ekir.2019.12.014. eCollection 2020 Mar. No abstract available.

2.

Podocyte Density and Albuminuria in Aging Diabetic Ins2± Mice with or Without Adenosine A1 Receptor Signaling.

Faulhaber-Walter R, Jiang L, Mizel D, Zerfas PM, Kopp JB, Schnermann JB, Chen L, Schiffer M.

Int J Nephrol Renovasc Dis. 2020 Feb 21;13:19-26. doi: 10.2147/IJNRD.S203810. eCollection 2020.

3.

Interferon lambda promotes immune dysregulation and tissue inflammation in TLR7-induced lupus.

Goel RR, Wang X, O'Neil LJ, Nakabo S, Hasneen K, Gupta S, Wigerblad G, Blanco LP, Kopp JB, Morasso MI, Kotenko SV, Yu ZX, Carmona-Rivera C, Kaplan MJ.

Proc Natl Acad Sci U S A. 2020 Mar 10;117(10):5409-5419. doi: 10.1073/pnas.1916897117. Epub 2020 Feb 24.

PMID:
32094169
4.

LNA-anti-miR-150 ameliorated kidney injury of lupus nephritis by inhibiting renal fibrosis and macrophage infiltration.

Luan J, Fu J, Chen C, Jiao C, Kong W, Zhang Y, Chang Q, Wang Y, Li D, Illei GG, Kopp JB, Pi J, Zhou H.

Arthritis Res Ther. 2019 Dec 11;21(1):276. doi: 10.1186/s13075-019-2044-2.

5.

miR-150 inhibitor ameliorates adriamycin-induced focal segmental glomerulosclerosis.

Qi H, Fu J, Luan J, Jiao C, Cui X, Cao X, Zhang Y, Wang Y, Kopp JB, Pi J, Zhou H.

Biochem Biophys Res Commun. 2020 Feb 12;522(3):618-625. doi: 10.1016/j.bbrc.2019.11.096. Epub 2019 Nov 29.

PMID:
31787235
6.

Genetic Testing for APOL1 Genetic Variants in Clinical Practice: Finally Starting to Arrive.

Kopp JB, Winkler CA.

Clin J Am Soc Nephrol. 2020 Jan 7;15(1):126-128. doi: 10.2215/CJN.01810219. Epub 2019 Nov 18. No abstract available.

PMID:
31740572
7.

APOL1 Nephropathy Risk Alleles and Risk of Sepsis in Blacks.

Chaudhary NS, Moore JX, Zakai NA, Judd SE, Naik RP, Limou S, Cushman M, Lange LA, Wang HE, Winkler CA, Irvin MR, Kopp JB, Gutiérrez OM.

Clin J Am Soc Nephrol. 2019 Dec 6;14(12):1733-1740. doi: 10.2215/CJN.04490419. Epub 2019 Nov 8.

PMID:
31704668
8.

Rationale and Design for a Phase 1 Study of N-Acetylmannosamine for Primary Glomerular Diseases.

Huizing M, Yardeni T, Fuentes F, Malicdan MCV, Leoyklang P, Volkov A, Dekel B, Brede E, Blake J, Powell A, Chatrathi H, Anikster Y, Carrillo N, Gahl WA, Kopp JB.

Kidney Int Rep. 2019 Jun 25;4(10):1454-1462. doi: 10.1016/j.ekir.2019.06.012. eCollection 2019 Oct.

9.

APOL1 Nephropathy Risk Alleles and Mortality in African American Adults: A Cohort Study.

Gutiérrez OM, Irvin MR, Zakai NA, Naik RP, Chaudhary NS, Estrella MM, Limou S, Judd SE, Cushman M, Kopp JB, Winkler CA.

Am J Kidney Dis. 2020 Jan;75(1):54-60. doi: 10.1053/j.ajkd.2019.05.027. Epub 2019 Sep 26.

PMID:
31563468
10.

Apolipoprotein L1 Testing in African Americans: Involving the Community in Policy Discussions.

Young BA, Blacksher E, Cavanaugh KL, Freedman BI, Fullerton SM, Kopp JB, Umeukeje EM, West KM, Wilson JG, Burke W; APOL1 Stakeholders Project.

Am J Nephrol. 2019;50(4):303-311. doi: 10.1159/000502675. Epub 2019 Sep 3.

PMID:
31480040
11.

APOL1 Kidney Risk Variants and Cardiovascular Disease: An Individual Participant Data Meta-Analysis.

Grams ME, Surapaneni A, Ballew SH, Appel LJ, Boerwinkle E, Boulware LE, Chen TK, Coresh J, Cushman M, Divers J, Gutiérrez OM, Irvin MR, Ix JH, Kopp JB, Kuller LH, Langefeld CD, Lipkowitz MS, Mukamal KJ, Musani SK, Naik RP, Pajewski NM, Peralta CA, Tin A, Wassel CL, Wilson JG, Winkler CA, Young BA, Zakai NA, Freedman BI.

J Am Soc Nephrol. 2019 Oct;30(10):2027-2036. doi: 10.1681/ASN.2019030240. Epub 2019 Aug 5.

PMID:
31383730
12.

Chronic kidney disease in propionic acidemia.

Shchelochkov OA, Manoli I, Sloan JL, Ferry S, Pass A, Van Ryzin C, Myles J, Schoenfeld M, McGuire P, Rosing DR, Levin MD, Kopp JB, Venditti CP.

Genet Med. 2019 Dec;21(12):2830-2835. doi: 10.1038/s41436-019-0593-z. Epub 2019 Jun 28.

13.

Optimal management of HIV- positive adults at risk for kidney disease in Nigeria (Renal Risk Reduction "R3" Trial): protocol and study design.

Aliyu MH, Wudil UJ, Ingles DJ, Shepherd BE, Gong W, Musa BM, Muhammad H, Sani MU, Abdu A, Nalado AM, Atanda A, Ahonkhai AA, Ikizler TA, Winkler CA, Kopp JB, Kimmel PL, Wester CW.

Trials. 2019 Jun 10;20(1):341. doi: 10.1186/s13063-019-3436-y.

14.

Renal Failure Patients in Disasters.

Lempert KD, Kopp JB.

Disaster Med Public Health Prep. 2019 Aug;13(4):782-790. doi: 10.1017/dmp.2018.142. Epub 2019 May 6.

15.

Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease.

Kikuchi K, Saigusa D, Kanemitsu Y, Matsumoto Y, Thanai P, Suzuki N, Mise K, Yamaguchi H, Nakamura T, Asaji K, Mukawa C, Tsukamoto H, Sato T, Oikawa Y, Iwasaki T, Oe Y, Tsukimi T, Fukuda NN, Ho HJ, Nanto-Hara F, Ogura J, Saito R, Nagao S, Ohsaki Y, Shimada S, Suzuki T, Toyohara T, Mishima E, Shima H, Akiyama Y, Akiyama Y, Ichijo M, Matsuhashi T, Matsuo A, Ogata Y, Yang CC, Suzuki C, Breeggemann MC, Heymann J, Shimizu M, Ogawa S, Takahashi N, Suzuki T, Owada Y, Kure S, Mano N, Soga T, Wada T, Kopp JB, Fukuda S, Hozawa A, Yamamoto M, Ito S, Wada J, Tomioka Y, Abe T.

Nat Commun. 2019 Apr 23;10(1):1835. doi: 10.1038/s41467-019-09735-4.

16.

APOL1 renal risk variants promote cholesterol accumulation in tissues and cultured macrophages from APOL1 transgenic mice.

Ryu JH, Ge M, Merscher S, Rosenberg AZ, Desante M, Roshanravan H, Okamoto K, Shin MK, Hoek M, Fornoni A, Kopp JB.

PLoS One. 2019 Apr 18;14(4):e0211559. doi: 10.1371/journal.pone.0211559. eCollection 2019.

17.

Survival Advantage of African American Dialysis Patients with End-Stage Renal Disease Causes Related to APOL1.

Lertdumrongluk P, Streja E, Rhee CM, Moradi H, Chang Y, Reddy U, Tantisattamo E, Kalantar-Zadeh K, Kopp JB.

Cardiorenal Med. 2019;9(4):212-221. doi: 10.1159/000496472. Epub 2019 Apr 17.

18.

Open-Label Clinical Trials of Oral Pulse Dexamethasone for Adults with Idiopathic Nephrotic Syndrome.

Cho ME, Branton MH, Smith DA, Bartlett L, Howard L, Reynolds JC, Rosenstein D, Sethi S, Nava MB, Barisoni L, Fervenza FC, Kopp JB.

Am J Nephrol. 2019;49(5):377-385. doi: 10.1159/000497064. Epub 2019 Apr 9.

PMID:
30965344
19.

c-Src is in the effector pathway linking uPAR and podocyte injury.

Kopp JB, Heymann J.

J Clin Invest. 2019 Apr 2;129(5):1827-1829. doi: 10.1172/JCI127927. eCollection 2019 Apr 2.

20.

Impact of APOL1 Genetic Variants on HIV-1 Infection and Disease Progression.

An P, Kirk GD, Limou S, Binns-Roemer E, Kopp JB, Winkler CA.

Front Immunol. 2019 Jan 24;10:53. doi: 10.3389/fimmu.2019.00053. eCollection 2019.

21.

One Actor, Many Roles: Histopathologies Associated With APOL1 Genetic Variants.

Kopp JB, Rosenberg AZ.

Adv Anat Pathol. 2019 May;26(3):215-219. doi: 10.1097/PAP.0000000000000221. Review.

PMID:
30624253
22.

Expanding the spectrum of APOL1-related renal disease: de novo collapsing glomerulopathy following kidney transplant.

Kopp JB.

Kidney Int. 2018 Dec;94(6):1048-1050. doi: 10.1016/j.kint.2018.09.006.

PMID:
30466562
23.

NPHS2 V260E Is a Frequent Cause of Steroid-Resistant Nephrotic Syndrome in Black South African Children.

Asharam K, Bhimma R, David VA, Coovadia HM, Qulu WP, Naicker T, Gillies CE, Vega-Warner V, Johnson RC, Limou S, Kopp JB, Sampson M, Nelson GW, Winkler CA.

Kidney Int Rep. 2018 Jul 29;3(6):1354-1362. doi: 10.1016/j.ekir.2018.07.017. eCollection 2018 Nov.

24.

APOL1 risk allele RNA contributes to renal toxicity by activating protein kinase R.

Okamoto K, Rausch JW, Wakashin H, Fu Y, Chung JY, Dummer PD, Shin MK, Chandra P, Suzuki K, Shrivastav S, Rosenberg AZ, Hewitt SM, Ray PE, Noiri E, Le Grice SFJ, Hoek M, Han Z, Winkler CA, Kopp JB.

Commun Biol. 2018 Nov 7;1:188. doi: 10.1038/s42003-018-0188-2. eCollection 2018.

25.

APOL1-Associated Nephropathy: A Key Contributor to Racial Disparities in CKD.

Freedman BI, Limou S, Ma L, Kopp JB.

Am J Kidney Dis. 2018 Nov;72(5 Suppl 1):S8-S16. doi: 10.1053/j.ajkd.2018.06.020. Review.

26.
27.

Fetal-Not Maternal-APOL1 Genotype Associated with Risk for Preeclampsia in Those with African Ancestry.

Reidy KJ, Hjorten RC, Simpson CL, Rosenberg AZ, Rosenblum SD, Kovesdy CP, Tylavsky FA, Myrie J, Ruiz BL, Haque S, Mozhui K, Nelson GW, David VA, Yang X, Suzuki M, Jacob J, Reznik SE, Kaskel FJ, Kopp JB, Winkler CA, Davis RL.

Am J Hum Genet. 2018 Sep 6;103(3):367-376. doi: 10.1016/j.ajhg.2018.08.002. Epub 2018 Aug 30.

28.

Genetics, Genomics, and Precision Medicine in End-Stage Kidney Disease.

Kopp JB, Winkler CA.

Semin Nephrol. 2018 Jul;38(4):317-324. doi: 10.1016/j.semnephrol.2018.05.002. Review.

PMID:
30082052
29.

Association of APOL1 With Heart Failure With Preserved Ejection Fraction in Postmenopausal African American Women.

Franceschini N, Kopp JB, Barac A, Martin LW, Li Y, Qian H, Reiner AP, Pollak M, Wallace RB, Rosamond WD, Winkler CA.

JAMA Cardiol. 2018 Aug 1;3(8):712-720. doi: 10.1001/jamacardio.2018.1827.

30.

APOL1 Nephropathy Risk Variants and Incident Cardiovascular Disease Events in Community-Dwelling Black Adults.

Gutiérrez OM, Irvin MR, Chaudhary NS, Cushman M, Zakai NA, David VA, Limou S, Pamir N, Reiner AP, Naik RP, Sale MM, Safford MM, Hyacinth HI, Judd SE, Kopp JB, Winkler CA.

Circ Genom Precis Med. 2018 Jun;11(6):e002098. doi: 10.1161/CIRCGEN.117.002098.

31.

Association of Sickle Cell Trait With Ischemic Stroke Among African Americans: A Meta-analysis.

Hyacinth HI, Carty CL, Seals SR, Irvin MR, Naik RP, Burke GL, Zakai NA, Wilson JG, Franceschini N, Winkler CA, David VA, Kopp JB, Judd SE, Adams RJ, Longstreth WT Jr, Egede L, Lackland DT, Taylor H, Manson JE, Howard V, Allison M, Gee BE, Correa A, Safford MM, Arnett DK, Howard G, Reiner AP, Cushman M.

JAMA Neurol. 2018 Jul 1;75(7):802-807. doi: 10.1001/jamaneurol.2018.0571.

32.

Kidney Diseases Associated with Human Immunodeficiency Virus Infection.

Cohen SD, Kopp JB, Kimmel PL.

N Engl J Med. 2018 Apr 26;378(17):1655-6. doi: 10.1056/NEJMc1800396. No abstract available.

PMID:
29694807
33.

Global glomerulosclerosis in primary nephrotic syndrome: including age as a variable to predict renal outcomes.

Kopp JB.

Kidney Int. 2018 May;93(5):1043-1044. doi: 10.1016/j.kint.2018.01.020.

PMID:
29680021
34.

Genetic Testing in Clinical Settings.

Franceschini N, Frick A, Kopp JB.

Am J Kidney Dis. 2018 Oct;72(4):569-581. doi: 10.1053/j.ajkd.2018.02.351. Epub 2018 Apr 11. Review.

35.

Apolipoprotein L1 nephropathies: 2017 in review.

Kopp JB, Roshanravan H, Okamoto K.

Curr Opin Nephrol Hypertens. 2018 May;27(3):153-158. doi: 10.1097/MNH.0000000000000399. Review.

PMID:
29389775
36.

ApoL1 renal risk variants induce aberrant THP-1 monocyte differentiation and increase eicosanoid production via enhanced expression of cyclooxygenase-2.

Lee H, Roshanravan H, Wang Y, Okamoto K, Ryu J, Shrivastav S, Qu P, Kopp JB.

Am J Physiol Renal Physiol. 2018 Jul 1;315(1):F140-F150. doi: 10.1152/ajprenal.00254.2017. Epub 2018 Jan 10.

37.

Randomized Clinical Trial Design to Assess Abatacept in Resistant Nephrotic Syndrome.

Trachtman H, Gipson DS, Somers M, Spino C, Adler S, Holzman L, Kopp JB, Sedor J, Overfield S, Elegbe A, Maldonado M, Greka A.

Kidney Int Rep. 2017 Aug 31;3(1):115-121. doi: 10.1016/j.ekir.2017.08.013. eCollection 2018 Jan.

38.

APOL1 Risk Variants Independently Associated With Early Cardiovascular Disease Death.

Hughson MD, Hoy WE, Mott SA, Bertram JF, Winkler CA, Kopp JB.

Kidney Int Rep. 2017 Aug 24;3(1):89-98. doi: 10.1016/j.ekir.2017.08.007. eCollection 2018 Jan.

39.

APOL1 Genotype and Renal Function of Black Living Donors.

Doshi MD, Ortigosa-Goggins M, Garg AX, Li L, Poggio ED, Winkler CA, Kopp JB.

J Am Soc Nephrol. 2018 Apr;29(4):1309-1316. doi: 10.1681/ASN.2017060658. Epub 2018 Jan 16.

40.

Kidney Diseases Associated with Human Immunodeficiency Virus Infection.

Cohen SD, Kopp JB, Kimmel PL.

N Engl J Med. 2017 Dec 14;377(24):2363-2374. doi: 10.1056/NEJMra1508467. Review. No abstract available. Erratum in: N Engl J Med. 2018 Apr 26; 378(17):1657.

PMID:
29236630
41.

Opposing Roles of Dendritic Cell Subsets in Experimental GN.

Brähler S, Zinselmeyer BH, Raju S, Nitschke M, Suleiman H, Saunders BT, Johnson MW, Böhner AMC, Viehmann SF, Theisen DJ, Kretzer NM, Briseño CG, Zaitsev K, Ornatsky O, Chang Q, Carrero JA, Kopp JB, Artyomov MN, Kurts C, Murphy KM, Miner JH, Shaw AS.

J Am Soc Nephrol. 2018 Jan;29(1):138-154. doi: 10.1681/ASN.2017030270. Epub 2017 Dec 7.

42.

Whole Exome Sequencing of Patients with Steroid-Resistant Nephrotic Syndrome.

Warejko JK, Tan W, Daga A, Schapiro D, Lawson JA, Shril S, Lovric S, Ashraf S, Rao J, Hermle T, Jobst-Schwan T, Widmeier E, Majmundar AJ, Schneider R, Gee HY, Schmidt JM, Vivante A, van der Ven AT, Ityel H, Chen J, Sadowski CE, Kohl S, Pabst WL, Nakayama M, Somers MJG, Rodig NM, Daouk G, Baum M, Stein DR, Ferguson MA, Traum AZ, Soliman NA, Kari JA, El Desoky S, Fathy H, Zenker M, Bakkaloglu SA, Müller D, Noyan A, Ozaltin F, Cadnapaphornchai MA, Hashmi S, Hopcian J, Kopp JB, Benador N, Bockenhauer D, Bogdanovic R, Stajić N, Chernin G, Ettenger R, Fehrenbach H, Kemper M, Munarriz RL, Podracka L, Büscher R, Serdaroglu E, Tasic V, Mane S, Lifton RP, Braun DA, Hildebrandt F.

Clin J Am Soc Nephrol. 2018 Jan 6;13(1):53-62. doi: 10.2215/CJN.04120417. Epub 2017 Nov 10.

43.

APOL1 Renal Risk Variants: Fertile Soil for HIV-Associated Nephropathy.

Kopp JB, Heymann J, Winkler CA.

Semin Nephrol. 2017 Nov;37(6):514-519. doi: 10.1016/j.semnephrol.2017.07.004. Review.

44.

FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity.

Wang XX, Wang D, Luo Y, Myakala K, Dobrinskikh E, Rosenberg AZ, Levi J, Kopp JB, Field A, Hill A, Lucia S, Qiu L, Jiang T, Peng Y, Orlicky D, Garcia G, Herman-Edelstein M, D'Agati V, Henriksen K, Adorini L, Pruzanski M, Xie C, Krausz KW, Gonzalez FJ, Ranjit S, Dvornikov A, Gratton E, Levi M.

J Am Soc Nephrol. 2018 Jan;29(1):118-137. doi: 10.1681/ASN.2017020222. Epub 2017 Oct 31.

45.

HIV-1 viral protein R (Vpr) induces fatty liver in mice via LXRα and PPARα dysregulation: implications for HIV-specific pathogenesis of NAFLD.

Agarwal N, Iyer D, Gabbi C, Saha P, Patel SG, Mo Q, Chang B, Goswami B, Schubert U, Kopp JB, Lewis DE, Balasubramanyam A.

Sci Rep. 2017 Oct 17;7(1):13362. doi: 10.1038/s41598-017-13835-w.

46.

APOL1 nephropathy risk variants do not associate with subclinical atherosclerosis or left ventricular mass in middle-aged black adults.

Gutiérrez OM, Limou S, Lin F, Peralta CA, Kramer HJ, Carr JJ, Bibbins-Domingo K, Winkler CA, Lewis CE, Kopp JB.

Kidney Int. 2018 Mar;93(3):727-732. doi: 10.1016/j.kint.2017.08.019. Epub 2017 Oct 14.

47.

A tripartite complex of suPAR, APOL1 risk variants and αvβ3 integrin on podocytes mediates chronic kidney disease.

Hayek SS, Koh KH, Grams ME, Wei C, Ko YA, Li J, Samelko B, Lee H, Dande RR, Lee HW, Hahm E, Peev V, Tracy M, Tardi NJ, Gupta V, Altintas MM, Garborcauskas G, Stojanovic N, Winkler CA, Lipkowitz MS, Tin A, Inker LA, Levey AS, Zeier M, Freedman BI, Kopp JB, Skorecki K, Coresh J, Quyyumi AA, Sever S, Reiser J.

Nat Med. 2017 Aug;23(8):945-953. doi: 10.1038/nm.4362. Epub 2017 Jun 26.

48.

Gingival recession in mandibular incisors and symphysis morphology-a retrospective cohort study.

Mazurova K, Kopp JB, Renkema AM, Pandis N, Katsaros C, Fudalej PS.

Eur J Orthod. 2018 Apr 6;40(2):185-192. doi: 10.1093/ejo/cjx046.

PMID:
28637273
49.

Chronic Kidney Disease in the Aging Human Immunodeficiency Virus-Infected Population.

Kopp JB.

J Infect Dis. 2017 Sep 15;216(6):619-621. doi: 10.1093/infdis/jix205. No abstract available. Erratum in: J Infect Dis. 2017 Sep 15;216(6):786.

50.

APOL1 genetic variants are not associated with longitudinal blood pressure in young black adults.

Chen TK, Estrella MM, Vittinghoff E, Lin F, Gutierrez OM, Kramer H, Lewis CE, Kopp JB, Allen NB, Winkler CA, Bibbins-Domingo KB, Peralta CA.

Kidney Int. 2017 Oct;92(4):964-971. doi: 10.1016/j.kint.2017.03.028. Epub 2017 May 23.

Supplemental Content

Support Center